CTLA4 and melanoma: The dire situation was changed in 2011 when the U.S. Food and Drug Administration (FDA) approved ipilimumab, an anti-human CTLA-4 monoclonal antibody that successfully improved the survival of melanoma patients in phase III clinical trials,1 opening a new era of immunotherapy on ICBs.